Scientist

James Matthaei

James received his PhD from the University of Washington in Chemical Engineering. His thesis work was on the generation of an entirely new family of proteins capable of self-assembling into crystalline 2D arrays.

James did his post-doctoral work at Seattle Children’s Research Institute in Michael Jensen’s Lab.  He worked on universal CAR T cell therapies using bi-specific molecules to selectively target multiple types of cancer. These therapies are advancing to clinical trials.

James is a member of Sonoma’s Translational Development team in Seattle. He is working to optimize our initial cell therapy products along with developing the novel technologies for our next generation of cell therapies.